Literature DB >> 18521349

Ten-Year Follow-Up of a Patient with Metastatic Ewing's Sarcoma of the Pelvis.

Robert U Ashford1, Eugene V McCloskey, O Prakash Purohit, Christine E Ingram, Robert J Grimer, Robert E Coleman.   

Abstract

PATIENT: We report a 32-year-old women with a pelvic Ewing's sarcoma, who developed skeletal metastases within 20 months of diagnosis but following treatment remains disease-free at 10 years. DISCUSSION: Ewing's sarcoma is a highly malignant tumour of bone. Presentation of a pelvic tumour over the age of 30 years is extremely rare and associated with a poor prognosis. Early recurrence is also associated with an extremely grave prognosis. In our patient there was little or no response to salvage chemotherapy, but, against the odds, remission was induced with pamidronate and palliative radiotherapy to some but not all sites of disease.This remission has been maintained without additional therapy for a further 5 years.

Entities:  

Year:  2002        PMID: 18521349      PMCID: PMC2395498          DOI: 10.1080/1357714021000022140

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  5 in total

1.  Pelvic Ewing sarcoma: a retrospective analysis of 241 cases.

Authors:  C Hoffmann; S Ahrens; J Dunst; A Hillmann; W Winkelmann; A Craft; U Göbel; C Rübe; P A Voute; D Harms; H Jürgens
Journal:  Cancer       Date:  1999-02-15       Impact factor: 6.860

2.  Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome.

Authors:  E H Baldini; G D Demetri; C D Fletcher; J Foran; K C Marcus; S Singer
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

3.  Ewing sarcoma of the pelvis. Clinicopathological features and treatment.

Authors:  F J Frassica; D A Frassica; D J Pritchard; P J Schomberg; L E Wold; F H Sim
Journal:  J Bone Joint Surg Am       Date:  1993-10       Impact factor: 5.284

4.  Surgical indications for Ewing's sarcoma of the pelvis.

Authors:  R S Yang; J J Eckardt; F R Eilber; G Rosen; C A Forscher; F J Dorey; C M Kelly; R al-Shaikh
Journal:  Cancer       Date:  1995-10-15       Impact factor: 6.860

5.  The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Authors:  S P Jagdev; R E Coleman; C M Shipman; A Rostami-H; P I Croucher
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.